ArticleMolecular and cellular biochemistry2026
Curcumin improves myocardial redox status in an experimental model of rheumatoid arthritis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Curcumin, a natural polyphenol derived from turmeric, possesses potent antioxidant properties and represents a potential cardioprotective agent capable of mitigating myocardial oxidative stress associated with rheumatoid arthritis (RA). The aim of the study was to examine the cardioprotective effect of curcumin in an experimental model of rheumatoid arthritis. The study included 104 female Wistar albino rats, divided into 8 groups (n = 13 in each group): (1) CTRL (negative control, healthy rats without treatment), (2) CUR (positive control 1, curcumin 200 mg/kg three times a week for 4 weeks orally), (3) MTX (positive control 2, methotrexate 0.75 mg/kg twice a week for 4 weeks intraperitoneally), (4) RA (positive control 3, rats with Complete Freund's adjuvant (CFA)-induced RA), (5) RA+pCUR (rats with preventive administration of curcumin + CFA-induced RA), (6) RA+tCUR (rats with CFA-induced RA + therapeutic administration of curcumin), (7) RA + MTX+pCUR (rats with preventive administration of curcumin + CFA-induced RA + methotrexate), (8) RA + MTX+tCUR (rats with CFA-induced RA + therapeutic administration of curcumin + methotrexate). Pro-oxidant levels were determined in coronary venous effluent, antioxidant enzyme activities were assessed in heart tissue homogenates, and histopathological analyses of the synovium and myocardium were performed. Curcumin, particularly in the therapeutic regimen and in combination with methotrexate, significantly reduced pro-oxidant levels and lipid peroxidation. Curcumin also increased superoxide dismutase activity and restored reduced glutathione levels, whereas improvement in catalase activity was observed predominantly in the therapeutic regimens. Histopathological analyses demonstrated that curcumin exerted a protective effect on both synovial and myocardial tissues, attenuating RA-induced structural damage, reducing edema, and preserving myocardial architecture. These findings suggest that curcumin improves myocardial redox homeostasis and may contribute to cardioprotection in experimental RA.
Indexed as
Identifiers
42701982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.